Full-Time

Contracts and Pricing Execution – Senior Manager

Confirmed live in the last 24 hours

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$152.4k - $193.8k/yr

+ Bonus + Stock-based long-term incentives

Senior, Expert

Remote in USA

Category
Financial Planning and Analysis (FP&A)
Finance & Banking
Required Skills
Data Analysis
Requirements
  • Doctorate degree and 2 years of contracts, pricing, finance and/or analytics experience
  • Master’s degree and 4 years of contracts, pricing, finance and/or analytics experience
  • Bachelor’s degree and 6 years of contracts, pricing, finance and/or analytics experience
  • Associate’s degree and 10 years of contracts, pricing, finance and/or analytics experience
  • High school diploma / GED and 12 years of contracts, pricing, finance and/or analytics experience
Responsibilities
  • Manage government program price calculations and develop models to calculate and/or validate system calculations.
  • Identify and implement process efficiencies to streamline activities while maintaining compliance with financial controls.
  • Develop substantive pricing analytics that accurately address contracting strategies, reporting variances, and financial impacts of calculations and communicate key variance drivers and/or insights effectively to senior leadership.
  • Analyze potential contracting strategies and provide guidance on impact to federal pricing programs.
  • Implement new programs or changes to existing federal pricing programs based on regulatory updates.
  • Collaborate cross-functionally with team members in Contract Development, Coverage and Pricing, Trade & Distribution, Digital Technology & Innovation (DTI), Compliance, Corporate and External Audit, Finance and Accounting, and Law.
  • Collaborate with DTI team to develop and maintain pricing calculations in the Contracts and Pricing system and assess and resolve upstream data variances.
  • Use of strong and persuasive verbal communication skills to execute and communicate effectively in a highly fluid, interactive, matrixed environment.
  • Coach, motivate and provide career and technical advice to direct reports and others in the department.
  • Identify and document key internal and external risks that may impact Amgen’s ability to maintain compliance with its Government Program policies, methodologies, and procedures.
  • Engage with corporate and external auditors on SOX, financial and other audit related activities to fulfill Government Programs’ audit responsibilities.
  • Key stakeholder with project implementations and system upgrades.
Desired Qualifications
  • Experience in Model N Revenue Cloud.
  • Pharmaceutical or Biotechnology experience.
  • Understanding of the US commercial and government healthcare and reimbursement environment.
  • Demonstrated track record of increasing responsibility and leadership experience.
  • Solid experience solving complex business problems and managing analytics projects.
  • Strong organizational skills and communication skills
  • Previous experience providing and delivering information for decision making by executive management.
  • Ability to synthesize complex information, extract significant facts and communicate to broader team.
  • Problem solving that identifies and develops solutions to complex problems from a strategic and operational perspective.
  • Ability to manage staff and providing clear and concise expectations and have open development and feedback discussions.
  • Demonstrated ability to successfully manage multiple simultaneous and complex projects to completion.
  • Exceptional experience with Excel modeling; Tableau experience highly preferred.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a significant portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective therapeutic solutions and expanding its pipeline of potential new treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.